Dr. Kandeepan Ganeshalingam received his medical degree from the University of Aberdeen and a Master of Science Degree from the Imperial College School of Medicine, University of London. He was also the Faraday Research fellow at the National Heart and Lung Institute, UK. Following
a 10 year career as a physician in the National Health Service Hospitals, UK, he joined the oncology product development team at Roche in 2007. In this role, he played a significant role in product development with several successful submissions to EMA and FDA. In 2010, he moved to Vifor Pharma, Switzerland to become the global head of medical and clinical drug safety, where he played a leadership role in clinical development, regulatory submissions and safety risk management. In 2012, he returned to Roche Product Development Medical Affairs as senior medical director, in immunology and was subsequently promoted to group medical
director in oncology, where he led the global medical team responsible for multiple haematology/oncology products. In this role, he was instrumental in building clinical trial collaborations with academic groups and external pharmaceutical companies. In 2016, he joined Merck Sharp Dohme as the executive director, oncology therapeutic area head, European
clinical development.